Paraphernalia
AarXiv2023Cited 3×

New Horizons: Pioneering Pharmaceutical R&D with Generative AI from lab to the clinic -- an industry perspective

Guy Doron, Sam Genway, Mark A. Roberts, Sai Jasti

Abstract

This perspective reviews the challenges in pharmaceutical R&D and takes a three-horizon approach to explore the generative AI applications already delivering impact, the disruptive opportunities which are just around the corner, and the longer-term transformation which will shape the future of the industry. Selected applications are reviewed for their potential to drive increase productivity, accelerate timelines, improve the quality of research, data and decision making, and support a sustainable future for the industry. Recommendations are given for Pharma R&D leaders developing a generative AI strategy today which will lay the groundwork for getting real value from the technology and safeguarding future growth.

A figure from New Horizons: Pioneering Pharmaceutical R&D with Generative AI from lab to the clinic -- an industry perspective
fig. from the paper

§ The Valyu brief

Reading the full paper and taking notes. This takes a few seconds…

§ Ask this paper

Ask a question about this paper

Valyu reads the full text and answers from what the paper actually says.

Q.

Searching the other archives…

New Horizons: Pioneering Pharmaceutical R&D with Generative AI from lab to the clinic -- an industry perspective · Paraphernalia